Hubbry Logo
V-ATPaseV-ATPaseMain
Open search
V-ATPase
Community hub
V-ATPase
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
V-ATPase
V-ATPase
V-ATPase
View on Wikipedia
from Wikipedia
V-ATPase
V-ATPase schematic
Identifiers
SymbolV-ATPase
TCDB3.A.2
OPM superfamily5
OPM protein2bl2
Membranome226
V-ATPase, subunit c (Vo)
Membrane-spanning region of the V-type sodium ATPase from Enterococcus hirae. Calculated hydrocarbon boundaries of the lipid bilayer are shown by red and blue dots
Identifiers
SymbolATP-synt_C
PfamPF00137
InterProIPR002379
PROSITEPDOC00526
SCOP21aty / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit C (V1)
crystal structure of subunit C (vma5p) of the yeast v-atpase
Identifiers
SymbolV-ATPase_C
PfamPF03223
InterProIPR004907
SCOP21u7l / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit I/a
Identifiers
SymbolV_ATPase_I
PfamPF01496
InterProIPR002490
SCOP23rrk / SCOPe / SUPFAM
TCDB3.A.2
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit E
Identifiers
SymbolvATP-synt_E
PfamPF01991
Pfam clanCL0255
InterProIPR002842
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit d/d2
crystal structure of subunit C (yeast subunit d) of v-atpase
Identifiers
SymbolvATP-synt_AC39
PfamPF01992
InterProIPR002843
SCOP21r5z / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit H, N-terminal
crystal structure of the regulatory subunit H of the v-type atpase of saccharomyces cerevisiae
Identifiers
SymbolV-ATPase_H_N
PfamPF03224
Pfam clanCL0020
InterProIPR004908
SCOP21ho8 / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
V-ATPase, subunit G
Identifiers
SymbolV-ATPase_G
PfamPF03179
Pfam clanCL0255
InterProIPR005124
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary

Vacuolar-type ATPase (V-ATPase) is a highly conserved evolutionarily ancient enzyme with remarkably diverse functions in eukaryotic organisms.[1] V-ATPases acidify a wide array of intracellular organelles and pump protons across the plasma membranes of numerous cell types. V-ATPases couple the energy of ATP hydrolysis to proton transport across intracellular and plasma membranes of eukaryotic cells. It is generally seen as the polar opposite of ATP synthase because ATP synthase is a proton channel that uses the energy from a proton gradient to produce ATP. V-ATPase however, is a proton pump that uses the energy from ATP hydrolysis to produce a proton gradient.

The Archaea-type ATPase (A-ATPase) is a related group of ATPases found in archaea that often work as an ATP synthase. It forms a clade V/A-ATPase with V-ATPase. Most members of either group shuttle protons (H+
), but a few members have evolved to use sodium ions (Na+
) instead.

Roles played by V-ATPases

[edit]

V-ATPases are found within the membranes of many organelles, such as endosomes, lysosomes, and secretory vesicles, where they play a variety of roles crucial for the function of these organelles. For example, the proton gradient across the yeast vacuolar membrane generated by V-ATPases drives calcium uptake into the vacuole through an H+
/Ca2+
 antiporter system.[2] In synaptic transmission in neuronal cells, V-ATPase acidifies synaptic vesicles.[3] Norepinephrine enters vesicles by V-ATPase [citation needed].

V-ATPases are also found in the plasma membranes of a wide variety of cells such as intercalated cells of the kidney, osteoclasts (bone resorbing cells), macrophages, neutrophils, sperm, midgut cells of insects, and certain tumor cells.[4] Plasma membrane V-ATPases are involved in processes such as pH homeostasis, coupled transport, and tumor metastasis. V-ATPases in the acrosomal membrane of sperm acidify the acrosome. This acidification activates proteases required to drill through the plasma membrane of the egg. V-ATPases in the osteoclast plasma membrane pump protons onto the bone surface, which is necessary for bone resorption. In the intercalated cells of the kidney, V-ATPases pump protons into the urine, allowing for bicarbonate reabsorption into the blood. In addition, other variety of biological processes, such as toxin delivery, viral entry, membrane targeting, apoptosis, regulation of cytoplasmic pH, proteolytic process, and acidification of intracellular systems, are important roles of V-ATPases.[5]

V-ATPases also play a significant role in cell morphogenesis development. Disruption of the gene vma-1 gene which encodes for the catalytic subunit (A) of the enzyme severely impairs the rate of growth, differentiation, and the capacity to produce viable spores in fungus Neurospora crassa. [6]

Structure

[edit]

The yeast V-ATPase is the best characterized. There are at least thirteen subunits identified to form a functional V-ATPase complex, which consists of two domains. The subunits belong to either the Vo domain (membrane associated subunits, lowercase letters on the figure) or the V1 domain (peripherally associated subunits, uppercase letters on the figure).

The V1 includes eight subunits, A-H, with three copies of the catalytic A and B subunits, three copies of the stator subunits E and G, and one copy of the regulatory C and H subunits. In addition, the V1 domain also contains the subunits D and F, which form a central rotor axle.[7] The V1 domain contains tissue-specific subunit isoforms including B, C, E, and G. Mutations to the B1 isoform result in the human disease distal renal tubular acidosis and sensorineural deafness.

The Vo domain contains six different subunits, a, d, c, c', c", and e, with the stoichiometry of the c ring still a matter of debate with a decamer being postulated for the tobacco hornworm (Manduca sexta) V-ATPase. The mammalian Vo domain contains tissue-specific isoforms for subunits a and d, while yeast V-ATPase contains two organelle-specific subunit isoforms of a, Vph1p, and Stv1p. Mutations to the a3 isoform result in the human disease infantile malignant osteopetrosis, and mutations to the a4 isoform result in distal renal tubular acidosis, in some cases with sensorineural deafness.

The V1 domain is responsible for ATP hydrolysis, whereas the Vo domain is responsible for proton translocation. ATP hydrolysis at the catalytic nucleotide binding sites on subunit A drives rotation of a central stalk composed of subunits D and F, which in turn drives rotation of a barrel of c subunits relative to the a subunit. The complex structure of the V-ATPase has been revealed through the structure of the M. Sexta and Yeast complexes that were solved by single-particle cryo-EM and negative staining, respectively.[8][9][10] These structures have revealed that the V-ATPase has a 3-stator network, linked by a collar of density formed by the C, H, and a subunits, which, while dividing the V1 and Vo domains, make no interactions with the central rotor axle formed by the F, D, and d subunits. Rotation of this central rotor axle caused by the hydrolysis of ATP within the catalytic AB domains results in the movement of the barrel of c subunits past the a subunit, which drives proton transport across the membrane. A stoichiometry of two protons translocated for each ATP hydrolyzed has been proposed by Johnson.[11]

In addition to the structural subunits of yeast V-ATPase, associated proteins that are necessary for assembly have been identified. These associated proteins are essential for Vo domain assembly and are termed Vma12p, Vma21p, and Vma22p.[12][13][14][15] Two of the three proteins, Vma12p and Vma22p, form a complex that binds transiently to Vph1p (subunit a) to aid its assembly and maturation.[14][16][17][18] Vma21p coordinates assembly of the Vo subunits as well as escorting the Vo domain into vesicles for transport to the Golgi.[19]

V1

[edit]

The V1 domain of the V-ATPase is the site of ATP hydrolysis. Unlike Vo, the V1 domain is hydrophilic.[5] This soluble domain consists of a hexamer of alternating A and B subunits, a central rotor D, peripheral stators G and E, and regulatory subunits C and H. Hydrolysis of ATP drives a conformational change in the six A|B interfaces and with it rotation of the central rotor D. Unlike with the ATP synthase, the V1 domain is not an active ATPase when dissociated.

V1 Subunits[20]
Subunit Human Gene Note
A, B ATP6V1A, ATP6V1B1, ATP6V1B2 Catalytic hexamer.
C ATP6V1C1, ATP6V1C2
D ATP6V1D Central rotor stalk, responsible for ion specificity.
E, G ATP6V1E1, ATP6V1E2, ATP6V1G1, ATP6V1G2, ATP6V1G3
F ATP6V1F
H ATP6V1H

Subunit C

[edit]

V-ATPase (Vacuolar-ATPase) C represents the C terminal subunit that is part of the V1 complex, and is localised to the interface between the V1 and Vo complexes.[21]

Subunit C function
[edit]

The C subunit plays an essential role in controlling the assembly of V-ATPase, acting as a flexible stator that holds together the catalytic (V1) and membrane (VO) sectors of the enzyme .[22] The release of subunit C from the ATPase complex results in the dissociation of the V1 and Vo subcomplexes, which is an important mechanism in controlling V-ATPase activity in cells. Essentially, by creating a high electrochemical gradient and low pH, this powers the enzyme to create more ATP.

Subunits E, G

[edit]

These related subunits make up the stalk(s) of A/V-ATPase. They are important in assembly, and may function as pushrods in activity. E has a cap to connect to A/B, while G does not.[20] They likely evolved from a single protein by gene duplication.[23]

Subunit H

[edit]
Main article: ATP6V1H

Subunit H, is only involved in activity and not in assembly. This subunit also acts as an inhibitor of free V1 subunits; it stops ATP hydrolysis when V1 and Vo are dissociated.[24]

Vo

[edit]

The Vo domain is responsible for proton translocation. Unlike the F-type ATP synthase, the Vo domain generally transports protons against their own concentration gradient. Rotation of the Vo domain transports the protons in movement coordinated with the V1 domain, which is responsible for ATP hydrolysis. The Vo domain is hydrophobic and composed of several dissociable subunits.[5] These subunits are present in the Vo domain to make this a functional proton translocase; they are described below.

Vo Subunits[20]
Subunit Human Gene Note
a/I ATP6V0A1, ATP6V0A2, ATP6V0A4
c ATP6V0B, ATP6V0C Ring of varied size.
d/C ATP6V0D1, ATP6V0D2
e ATP6V0E1, ATP6V0E2 9 kDa hydrophobic assembly protein.
AC45/S1 ATP6AP1 Accessory subunit
S2 ATP6AP2 Accessory subunit

Subunit a/I

[edit]

The 116kDa subunit (or subunit a) and subunit I are found in the Vo or Ao complex of V- or A-ATPases, respectively. The 116kDa subunit is a transmembrane glycoprotein required for the assembly and proton transport activity of the ATPase complex. Several isoforms of the 116kDa subunit exist, providing a potential role in the differential targeting and regulation of the V-ATPase for specific organelles.

The function of the 116-kDa subunit is not defined, but its predicted structure consists of 6–8 transmembranous sectors, suggesting that it may function similar to subunit a of FO.

Subunit d/C

[edit]

Subunit d in V-ATPases, called subunit C in A-ATPases, is a part of the Vo complex. They fit onto the middle of the c ring, so are thought to function as a rotor. There are two versions of this subunit in eukaryotes, d/d1 and d2.[25]

In mammals, d1 (ATP6V0D1) is the ubiquitously expressed version and d2 (ATP6V0D2) is expressed in specific cell types only.[25]

Subunit c

[edit]

Similar to the F-type ATP synthase, the transmembrane region of the V-ATPase includes a ring of membrane-spanning subunits that are primarily responsible for proton translocation. Dissimilar from the F-type ATP synthase, however, the V-ATPase has multiple related subunits in the c-ring; in fungi such as yeast there are three related subunits (of varied stoichiometry) and in most other eukaryotes there are two.

V-ATPase assembly

[edit]

Yeast V-ATPases fail to assemble when any of the genes that encode subunits are deleted except for subunits H and c".[26][27][28] Without subunit H, the assembled V-ATPase is not active,[13][29] and the loss of the c" subunit results in uncoupling of enzymatic activity.[27]

The precise mechanisms by which V-ATPases assembly are still controversial, with evidence suggesting two different possibilities. Mutational analysis and in vitro assays have shown that preassembled Vo and V1 domains can combine to form one complex in a process called independent assembly. Support for independent assembly includes the findings that the assembled Vo domain can be found at the vacuole in the absence of the V1 domain, whereas free V1 domains can be found in the cytoplasm and not at the vacuole.[30][31] In contrast, in vivo pulse-chase experiments have revealed early interactions between Vo and V1 subunits, to be specific, the a and B subunits, suggesting that subunits are added in a step-wise fashion to form a single complex in a concerted assembly process.[32]

V-ATPase evolution

[edit]

A relatively new technique called ancestral gene resurrection has shed new light on the evolutionary history of the V-ATPase. It has been shown how the V-ATPase structure of the ancestral form consisting of two different proteins evolves into the fungi version with three different proteins.[33][34][35] The V-Type ATPase is similar to the archaeal (so called) A-Type ATP synthase, a fact that supports an archaeal origin of eukaryotes (like Eocyte Hypothesis, see also Lokiarchaeota). The exceptional occurrence of some lineages of archaea with F-type and of some lineages of bacteria with A-type ATPase respectively is regarded as a result of horizontal gene transfer.[36]

Regulation of V-ATPase activity

[edit]

V-ATPases are known to be specifically inhibited by macrolide antibiotics, such as concanamycin (CCA) and balifomycin A1.[37] In vivo regulation of V-ATPase activity is accomplished by reversible dissociation of the V1 domain from the Vo domain. After initial assembly, both the insect Manduca sexta and yeast V-ATPases can reversibly disassemble into free Vo and V1 domains after a 2- to 5-minute deprivation of glucose.[30] Reversible disassembly may be a general mechanism of regulating V-ATPase activity, since it exists in yeast and insects. Reassembly is proposed to be aided by a complex termed RAVE (regulator of H+
-ATPase of vacuolar and endosomal membranes).[38] Disassembly and reassembly of V-ATPases does not require new protein synthesis but does need an intact microtubular network.[39]

Human diseases

[edit]

Osteopetrosis

[edit]

Osteopetrosis is a generic name that represents a group of heritable conditions in which there is a defect in osteoclastic bone resorption. Both dominant and recessive osteopetrosis occur in humans.[40][41] Autosomal dominant osteopetrosis shows mild symptoms in adults experiencing frequent bone fractures due to brittle bones.[40] A more severe form of osteopetrosis is termed autosomal recessive infantile malignant osteopetrosis.[41][42][43] Three genes that are responsible for recessive osteopetrosis in humans have been identified. Their products are all directly involved in the proton generation and secretion pathways that are essential for bone resorption. One gene is carbonic anhydrase II (CAII), which, when mutated, causes osteopetrosis with renal tubular acidosis (type 3).[44] Mutations to the chloride channel CLC-7 gene also lead to both dominant and recessive osteopetrosis.[40][45] Approximately 50% of patients with recessive infantile malignant osteopetrosis have mutations to the a3 subunit isoform of V-ATPase.[42][45][46] In humans, 26 mutations have been identified in V-ATPase subunit isoform a3, found in osteoclasts, that result in the bone disease autosomal recessive osteopetrosis.[42][41][46][47]

Distal renal tubular acidosis (dRTA)

[edit]

The importance of V-ATPase activity in renal proton secretion is highlighted by the inherited disease distal renal tubular acidosis. In all cases, renal tubular acidosis results from a failure of the normal renal mechanisms that regulate systemic pH. There are four types of renal tubular acidosis. Type 1 is distal renal tubular acidosis and results from a failure of the cortical collecting duct to acidify the urine below pH 5.[48] Some patients with autosomal recessive dRTA also have sensorineural hearing loss.[49] Inheritance of this type of RTA results from either mutations to V-ATPase subunit isoform B1 or isoform a4 or mutations of band 3 (also called AE1), a Cl-/HCO3- exchanger.[49][50][51] Twelve different mutations to V-ATPase isoform B1[52] and twenty-four different mutations in a4 lead to dRTA.[52][49] Reverse transcription polymerase chain reaction studies have shown expression of the a4 subunit in the intercalated cell of the kidney and in the cochlea.[52] dRTA caused by mutations in the a4 subunit gene in some cases can be associated with deafness due to a failure to normally acidify the endolymph of the inner ear.[51]

X-linked myopathy with excessive autophagy (XMEA)

[edit]

X-linked myopathy with excessive autophagy is a rare genetic disease resulting from mutations in the VMA21 gene.[53] The disease has a childhood onset and results in a slowly progressive muscle weakness, typically beginning in the legs, and some patients can eventually require wheelchair assistance with advanced age. The Vma21 protein assists in assembly of the V-ATPase, and XMEA-associated mutations result in decreased activity of the V-ATPase and increased lysosomal pH.[53]

Nomenclature

[edit]

The term Vo has a lowercase letter "o" (not the number "zero") in subscript. The "o" stands for oligomycin, which binds to the homologous region in F-ATPase. It is worth noting that the human gene notations at NCBI designate it as "zero" rather than the letter "o". For example, the gene for the human c subunit of Vo is listed in NCBI gene database as "ATP6V0C" (with a zero), rather than "ATP6VOC" (with an "o"). Many pieces of literature make this mistake as well.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

V-ATPase

View on Grokipedia
from Grokipedia
The vacuolar-type H⁺-ATPase (V-ATPase) is a highly conserved, multisubunit complex that functions as an ATP-driven in eukaryotic cells, acidifying intracellular compartments such as endosomes, lysosomes, and the Golgi apparatus while also facilitating proton transport across the plasma membrane. This proton translocation establishes electrochemical gradients essential for cellular processes including membrane trafficking, protein degradation, , and pH . V-ATPases are ubiquitous in eukaryotes, with homologs in and , and their activity is the primary mechanism for organellar acidification. Structurally, V-ATPases are composed of two principal domains: the peripheral V₁ domain, a soluble complex responsible for , and the integral membrane V₀ domain, which forms a proton-conducting pathway. The V₁ domain includes eight subunit types (A₃B₃C₂DEFGH), forming a hexameric catalytic head that drives rotation of a central rotor stalk upon ATP binding and , while the V₀ domain comprises six subunit types (a, d, e, c₉ [or variants], c', c'') organized into a c-ring that rotates to translocate protons. High-resolution cryo-EM structures, including those from synaptic vesicles, have revealed the enzyme's rotary mechanism, lipid interactions stabilizing the c-ring, and assembly states such as intact V₁V₀ complexes or V₀-only forms. Isoforms, particularly of the transmembrane a subunit (e.g., Vph1p for vacuoles, Stv1p for Golgi/endosomes), confer organelle-specific targeting and modulate proton pumping efficiency, with vacuolar forms exhibiting higher activity than Golgi counterparts. V-ATPases play critical physiological roles across tissues, including in osteoclasts via extracellular acidification, renal acid secretion in intercalated cells, sperm maturation, and loading into synaptic vesicles through proton gradient-driven secondary . In plants and fungi, they maintain vacuolar for and storage. Their dysregulation contributes to pathologies such as , , neurodegenerative disorders, and cancer invasiveness, where elevated activity promotes tumor . Activity is regulated by reversible dissociation of V₁ and V₀ domains in response to glucose availability or , isoform-specific lipid dependencies (e.g., PI(4)P enhancing Golgi forms), and accessory factors like the complex for assembly or for synaptic stabilization.

Functions

Organelle Acidification

V-ATPase is a multi-subunit complex that functions as an ATP-driven , hydrolyzing ATP to translocate hydrogen ions (H⁺) across cellular membranes and thereby generating electrochemical proton gradients essential for intracellular acidification. This rotary mechanism couples the energy from in the peripheral V₁ domain to proton transport through the membrane-embedded V₀ domain, maintaining acidic environments in various s. In eukaryotic cells, V-ATPase primarily acidifies lysosomes to a of approximately 4.5–5.0, which is crucial for the optimal activity of acid hydrolases involved in macromolecular degradation. In and fungi, V-ATPase drives vacuolar acidification to levels around 5.0–5.5, essential for homeostasis, nutrient storage, and activation of vacuolar hydrolases. Endosomes are also acidified by V-ATPase in a gradient manner, typically dropping from pH 6.5 in early endosomes to pH 5.5 in late endosomes, facilitating ligand-receptor dissociation and directing for recycling or degradation. Similarly, the trans-Golgi network and Golgi apparatus are maintained at mildly acidic levels (around 6.0–6.5) by V-ATPase, supporting post-translational modifications such as and proper protein sorting. The acidification driven by V-ATPase has profound physiological impacts: in lysosomes, the low activates resident hydrolases to break down engulfed materials, ensuring and cellular waste management. In plant vacuoles, the proton gradient powers secondary of ions like and cations, contributing to osmotic regulation and stress responses. In endosomes, protonation-induced conformational changes dissociate from their receptors, enabling receptor to the plasma membrane and ligand delivery to lysosomes for degradation. Across these compartments, the resulting electrochemical gradients power secondary of ions, , and other solutes via symporters and antiporters. Quantitatively, V-ATPase exhibits a proton pumping rate of approximately 100 H⁺ per second per complex under conditions, reflecting its high efficiency in generating gradients. The stoichiometry of transport couples the of one ATP molecule to the translocation of 2–4 protons, balancing input with the thermodynamic demands of maintaining organelle acidity against passive leaks.

Cellular Homeostasis and Signaling

V-ATPase contributes to cytosolic in specialized cells by localizing to the plasma , where it facilitates proton to counteract intracellular acidification during high metabolic activity. In osteoclasts, for instance, V-ATPase isoforms containing the subunit are recruited to the ruffled border plasma , pumping protons into the resorption lacuna to dissolve while helping maintain neutral cytosolic through coordinated ion fluxes. This process is essential for preventing cytosolic in these highly active cells, as unchecked proton accumulation could impair enzymatic functions and cell viability. To ensure electroneutrality during proton transport, plasma membrane V-ATPase activity is tightly coupled to secondary transporters and channels. In osteoclasts, the electrogenic proton pumping generates a positive that is dissipated by Cl⁻ channels, such as ClC-7, allowing chloride efflux alongside protons to support sustained acidification without excessive voltage buildup. Similarly, in renal intercalated cells, V-ATPase couples with basolateral Na⁺/H⁺ exchangers (e.g., NHE1) to recycle sodium and further stabilize cytosolic by extruding excess protons generated from metabolic processes. These interactions prevent membrane hyperpolarization and maintain ion gradients critical for cellular . Beyond balance, V-ATPase serves as a key sensor in nutrient signaling pathways, particularly by integrating and glucose availability to regulate the mechanistic target of rapamycin complex 1 (). Lysosomal V-ATPase interacts directly with the Ragulator complex and Rag GTPases, forming a supercomplex that detects intracellular levels; upon sufficiency, this interaction promotes GDP-to-GTP exchange on /B, recruiting to the lysosomal surface for activation and subsequent promotion of and protein synthesis. Glucose sensing similarly involves V-ATPase, where its assembly and activity increase under glucose starvation via AMPK signaling, facilitating inhibition and shifting toward . In autophagy regulation, V-ATPase-mediated nutrient sensing fine-tunes lysosomal content monitoring to control autophagosome-lysosome fusion and degradation. When are depleted, reduced V-ATPase-Rag- signaling deactivates , relieving its inhibition on autophagy initiation factors like ULK1 and TFEB, thereby enhancing autophagic flux to recycle cellular components for survival. This mechanism exemplifies V-ATPase's role as a bidirectional regulator, linking lysosomal to broader pathways.

Extracellular and Tissue-Specific Roles

V-ATPases localize to the plasma in specialized cell types, where they drive extracellular proton essential for physiological processes such as and urinary acidification. In osteoclasts, the bone-resorbing cells, V-ATPases are targeted to the ruffled border , a highly folded domain that forms a sealed compartment called the resorption lacuna adjacent to the surface; here, they pump protons outward to acidify the lacuna, dissolving and enabling subsequent matrix degradation by proteases. This acidification lowers the local to approximately 4.5–5.0, creating conditions for efficient dissolution during . Similarly, in renal α-intercalated cells of the collecting duct, plasma V-ATPases secrete protons into the tubular lumen to acidify , thereby excreting excess acid and maintaining systemic balance. In , plasma V-ATPases in energize proton extrusion to drive K⁺ uptake via secondary transporters, facilitating stomatal opening for and transpiration control. Tissue-specific isoforms of V-ATPase subunits confer targeted localization and function in these cells. The a4 isoform (encoded by ATP6V0A4) is predominantly expressed in kidney intercalated cells and epididymal clear cells, directing V-ATPases to the apical plasma membrane for proton secretion into the ; in this isoform lead to impaired acidification and . In contrast, the a3 isoform (encoded by ATP6V0A3 or Tcirg1) is enriched in osteoclasts, where it facilitates assembly and membrane insertion of the at the ruffled border, with its deficiency resulting in severe due to failed . These isoform-specific targeting mechanisms ensure precise control of extracellular acidification in distinct tissues. Beyond normal , V-ATPases contribute to pathological extracellular modulation, particularly in the , where their activity promotes cancer progression. In various cancers, including and colorectal, upregulated plasma membrane V-ATPases extrude protons to acidify the extracellular , creating a low-pH milieu that enhances tumor cell invasion, , and by activating matrix-degrading enzymes and altering . This acidification is exacerbated by the Warburg effect, where glycolytic metabolism generates excess protons, and V-ATPase inhibition has been shown to reverse invasive phenotypes in preclinical models. V-ATPases also interact with the extracellular matrix through acidification-dependent mechanisms that facilitate tissue remodeling. In processes involving matrix turnover, such as cancer invasion and potentially , extracellular proton secretion by V-ATPases activates s like cathepsins and matrix metalloproteinases, promoting degradation and cellular migration across the matrix. For instance, in invasive cells, this localized acidification optimizes function at the cell-matrix interface, aiding ECM breakdown without intracellular involvement.

Structure

Overall Architecture

The vacuolar-type H⁺-ATPase (V-ATPase) is a large, multi-subunit complex with a of approximately 1 MDa, essential for proton transport across eukaryotic membranes. It is organized into two primary domains: the soluble, cytoplasmic V₁ domain, which catalyzes to provide energy, and the membrane-embedded V₀ domain, which facilitates proton translocation through the . This domain organization enables V-ATPase to function as a primary active transporter, acidifying intracellular compartments such as lysosomes, endosomes, and secretory vesicles. V-ATPase operates via a rotary mechanism, resembling a , in which a central assembly rotates relative to a stationary framework. The comprises the central stalk subunits and in V₁, connected to subunit d and the oligomeric c-ring in V₀. The includes peripheral arms formed by subunits C, E, G, and H, which connect the catalytic A₃B₃ hexamer in V₁ to the membrane-embedded subunit a and associated components in V₀, preventing unproductive rotation and coupling to proton movement. Recent cryo-electron microscopy (cryo-EM) structures of intact mammalian V-ATPases, resolved at overall resolutions of ~3 , have illuminated this in detail. These studies reveal the three-fold of the V₁ domain's A₃B₃ catalytic head and a c-ring composed of 10 subunits (nine c-subunits and one c″-subunit) in mammalian species, which determines the stoichiometry of protons translocated per ATP hydrolyzed.

V1 Peripheral Domain

The V1 peripheral domain of V-ATPase is the cytoplasmic, ATP-hydrolyzing sector responsible for converting from ATP into mechanical rotation. It forms a globular head approximately 10-15 nm in diameter, connected flexibly to the membrane-embedded V0 domain via a central stalk. This domain exhibits threefold rotational pseudosymmetry and is composed of multiple subunits that assemble into a catalytic hexamer and supporting elements. The core of the V1 domain is an A₃B₃ heterohexamer, where three A and three B subunits alternate to form the catalytic machinery. Three ATP-binding pockets are located at the interfaces between A and B subunits, specifically within the nucleotide-binding domains of these subunits. Sequential at these non-equivalent sites powers stepwise rotations of approximately 120° per cycle, driving the central rotor and ultimately proton translocation in the coupled V0 domain. Supporting the catalytic hexamer are stator and rotor components that ensure efficient energy transfer without slippage. The central stalk consists of subunits D and F, which form the rotating shaft linking V1 to the V0 c-ring. Peripheral stator arms, comprising subunits E and G, connect the catalytic core to the base of V1, stabilizing it against during . Subunit C acts as a regulatory element that links the V1 domain to V0, facilitating assembly and modulating activity, while subunit H provides inhibitory regulation in the detached V1 domain by stabilizing an ADP-inhibited state at a catalytic site. Recent cryo-EM studies have provided detailed views of V1 conformational states during catalysis, revealing three distinct rotary positions separated by 120° rotations. In human V-ATPase, these states are modulated by accessory proteins like mEAK7, which binds in state 2 to activate the enzyme by opening a catalytic site, and TLDc proteins, which favor inhibitory disassembly in state 1. Such insights highlight how nucleotide-driven transitions between open, closed, and semi-closed conformations of the A-B interfaces coordinate the catalytic cycle.

V0 Integral Domain

The V0 integral domain of the vacuolar-type H⁺-ATPase (V-ATPase) is the membrane-embedded sector that translocates protons across cellular membranes, coupling this to the rotary motion driven by the cytoplasmic V1 domain. Composed primarily of subunits a, d, e, and a rotating c-ring formed by multiple proteolipid c-subunits, the V0 domain operates through a mechanism where proton binding and release to the c-ring facilitate directional . This enables V-ATPase to acidify organelles such as lysosomes and endosomes, as well as contribute to plasma membrane proton extrusion in specialized cells. The proton pathway in V0 begins with protons entering from the through an access half-channel formed by the transmembrane helices of subunit a, where they protonate the essential residue (typically glutamate) on the lipid-exposed helix of a c-subunit in the rotating ring. As the c-ring rotates, driven by in V1, the protonated carboxylate moves away from the access channel and aligns with an exit half-channel in subunit a on the luminal side, allowing and release into the compartment. A conserved residue in subunit a acts as a , preventing by interacting electrostatically with the carboxylates during rotation. This half-channel ensures efficient, unidirectional proton flow without a continuous aqueous pore. The of the c-ring varies across , typically comprising 10–14 c-subunits, each with four transmembrane α-helices arranged in a structure that accommodates molecules between helices for stability and rotation. In mammals and , the ring contains 10 subunits, establishing an H⁺/ATP ratio of approximately 10/3 (∼3.3 protons per ATP hydrolyzed, given three catalytic sites in V1), while c-rings in some archaeal A-ATPases vary up to 13 subunits, yielding higher ratios up to ∼4. The c-subunits feature a critical aspartate or glutamate residue in the second transmembrane , which alternates between protonated (neutral) and deprotonated (charged) states to carry protons around the ring; in , one specialized c″ subunit has an asymmetric glutamate positioning that influences ring assembly. Subunit a, a large with multiple isoforms (a1–a4 in mammals), forms the static scaffold with its half-channels and is isoform-specific for targeting V-ATPase to distinct , such as endolysosomes (a1) or the plasma (a2); mutations in a isoforms are linked to diseases including and due to impaired acidification. Subunit d serves as a rotor connector, linking the c-ring to the central stalk of V1 (subunits D and F) to transmit efficiently during . Subunit e functions as an accessory component, aiding V0 assembly, membrane insertion, and potentially stabilizing stator interactions, though its precise role in proton transport remains accessory. The V0 domain interfaces with V1 through multiple peripheral stalks (primarily subunits E, G, and H), which resist counter-rotation and maintain mechanical coupling without slipping. Recent high-resolution cryo-EM structures from 2024 reveal specific V0 interactions with the protein , mediated by subunits a and e2 via an electrostatic interface of ∼350 Ų, suggesting a role in stabilizing V-ATPase on neuronal membranes and potentially modulating activity during .

Assembly and Localization

Biosynthesis and Subunit Assembly

The V-ATPase is a multi-subunit complex whose components are all encoded by nuclear genes and synthesized on free cytosolic ribosomes, with the exception of the transmembrane subunits of the V0 domain (a, c, d, and e), which undergo co-translational insertion into the (ER) membrane via the Sec61 translocon. The eight V1 subunits (A–H) are translated in the and fold independently before assembling into a soluble peripheral complex, whereas the five core V0 subunits integrate into the ER membrane during or shortly after synthesis to form the proton-translocating sector. This spatial separation ensures that V1 maturation occurs in the , while V0 biogenesis is coupled to the secretory pathway in the ER. Assembly of the V1 domain proceeds sequentially in the cytosol, initiating with the formation of the catalytic A3B3 hexameric core, which serves as a scaffold for subsequent incorporation of the central rotor subunits D and F, followed by the peripheral stator elements C, E (in duplicate), G, and H. In yeast, the RAVE chaperone complex (comprising Rav1p, Rav2p, and Skp1p) is essential for stable V1 assembly by binding to cytosolic V1 sectors, stabilizing them against degradation, and facilitating V1-V0 association during initial biosynthesis and reassembly. For the V0 domain, assembly occurs in the ER membrane and begins with oligomerization of multiple c-subunits into a rotary c-ring (typically 10 copies in yeast), which then associates with the membrane-embedded a-subunit and the accessory d and e subunits; this process is orchestrated by ER-resident chaperones Vma12p, Vma21p, and Vma22p, where Vma21p transiently binds the nascent c-ring to promote its interaction with the a-subunit and ensure structural integrity. The fully assembled V0 complex exits the ER via COPII vesicles for transport to the Golgi, where it awaits V1 docking, while incomplete V1 remains cytosolic until maturation. In metazoans, a recently identified heterotrimeric chaperone complex facilitates V-ATPase holoenzyme assembly, highlighting conserved yet diversified mechanisms across eukaryotes. Quality control mechanisms rigorously monitor subunit folding and assembly to prevent accumulation of dysfunctional complexes. Misfolded or unassembled V0 subunits, such as those bearing disease-associated mutations, are recognized by ER chaperones and targeted for ER-associated degradation (ERAD), involving retrotranslocation to the cytosol and ubiquitin-mediated proteasomal breakdown; for instance, the R444L mutation in the human a3 subunit (ATP6V0A3) causes ER retention and rapid ERAD, contributing to infantile malignant osteopetrosis. Similarly, absence of key assembly factors like Vma21p destabilizes V0 intermediates, triggering their degradation and ensuring only properly stoichiometrically balanced complexes proceed. The V1 domain exhibits fixed stoichiometry (3A:3B:1C:1D:2E:1F:1G:1H), while V0 maintains one each of a, d, and e subunits alongside a variable c-ring size (8–14 c-subunits across species, influencing proton stoichiometry). These controls maintain cellular homeostasis by linking assembly fidelity to V-ATPase function.

Membrane Insertion and Trafficking

The V0 integral domain of V-ATPase is assembled in the (ER), where transmembrane subunits such as a, d, and e integrate into the membrane prior to association with other V0 components. Once formed, the V0 complex is packaged into COPII-coated vesicles at ER exit sites for anterograde transport to the Golgi apparatus, where it recruits the cytosolic V1 peripheral domain to complete the holoenzyme. This process ensures proper maturation and prevents premature proton pumping in the ER, with disruptions in COPII function leading to retention of V0 at ER exit sites. Targeting of the assembled V-ATPase to specific intracellular membranes is mediated by isoform-specific motifs in the a-subunit, particularly within its cytosolic N-terminal domain, which serves as a regulatory hub for localization signals. For lysosomal sorting, the a-subunit isoform V0a1 contains conserved dileucine () and tyrosine-based motifs that interact with adaptor protein complexes; the dileucine motif at positions 147–148 binds AP-2 for initial endocytic routing to early endosomes, followed by dissociation and handover to AP-3 for delivery to late endosomes and lysosomes. In , analogous motifs in the Stv1 a-isoform direct Golgi/endosomal localization via phosphoinositide binding, while Vph1 directs vacuolar targeting, highlighting the role of these signals in specificity. In polarized epithelial cells, such as renal intercalated cells, V-ATPase insertion into the apical plasma membrane occurs via exocytosis from recycling endosomal vesicles, enabling regulated proton secretion into the urine during acidosis. This trafficking involves calcium-dependent SNARE-mediated fusion and cytoskeletal elements like microtubules and actin, with V-ATPase-rich vesicles rapidly shuttling to the membrane in response to pH stimuli. For maintenance of localization, retrieval from endosomes back to the trans-Golgi network (TGN) relies on retrograde pathways, including the retromer complex, which is essential for Golgi retention of specific a-isoforms like Stv1 in yeast and ensures recycling of the pump away from degradative compartments. The WASH complex further aids this retrieval by promoting actin polymerization to neutralize endosomal vesicles containing V-ATPase prior to retrograde transport.

Mechanism of Action

Rotary Catalysis in V1

The rotary catalysis in the V1 domain of V-ATPase converts the chemical energy from ATP hydrolysis into mechanical rotation of the central rotor, driving proton translocation in the associated V0 domain. The V1 sector consists of a hexameric A3B3 ring of catalytic subunits arranged alternately, with three catalytic sites at the A-B interfaces, and a central DF rotor shaft that interacts with these sites to induce conformational changes. ATP binding and hydrolysis at these sites cause asymmetric distortions in the A3B3 ring, propagating torque to rotate the rotor in 120° steps counterclockwise (viewed from the membrane), with each full 360° rotation requiring hydrolysis of three ATP molecules. This mechanism shares homology with F-ATP synthase but features distinct dwell times influenced by V1-specific elements like the peripheral stator subunits. In isolated V1, rotation proceeds through 120° steps with dwells corresponding to catalytic events, including substeps of ~40° triggered by ATP binding and ~80° associated with ADP release and , which generates the power stroke initiated at the ABsemi conformation and coordinated by the subunit H to prevent wasteful . However, in the full V0V1 holoenzyme, the rotation is geared down by the c-ring , manifesting as smaller steps (e.g., 36° for a 10-subunit c-ring), with catalytic dwells occurring every three mechanical steps to ensure . Single-molecule studies confirm tight chemo-mechanical under physiological conditions. The overall energy conversion in V-ATPase follows the reversible equation: ADP+Pi+nH(out)+⇌ATP+nH(in)+\text{ADP} + \text{P}_\text{i} + n\text{H}^+_\text{(out)} \rightleftharpoons \text{ATP} + n\text{H}^+_\text{(in)} where n≈3−4n \approx 3-4 protons per ATP, depending on the c-ring stoichiometry in V0 (e.g., 4 for bacterial dodecamer rotors); in synthesis mode under favorable proton gradients, the reaction reverses to produce ATP. Single-molecule studies using probes like Janus nanoparticles or magnetic beads have measured rotation speeds of ~10-100 Hz under physiological loads (e.g., ~5 revolutions per second or 15 steps per second at 5 mM ATP), generating torque on the order of tens of pN·nm (e.g., 20-22 pN·nm), sufficient to overcome viscous drag and drive proton pumping. Recent cryo-EM structures from 2023-2024 have captured transient asymmetric conformations in the V1 A/B subunits, revealing sequential ATP binding that transitions the from ground to steady-state states. These include states with ATP at open (ABopen), semi-open (ABsemi), and closed (ABclosed) sites, showing distinct occupancy and β-zipper interactions with the DF shaft that underpin the rotary . For instance, intermediates like V2ATP (ATP at two sites) and V3ATP (ATP/ADP at all three) highlight how binding induces progressive distortions, with resolutions down to 2.8 confirming the catalytic site's hydrolysis-ready geometry in ABsemi. As of October 2025, additional structures from Thermus thermophilus during ATP synthesis have provided insights into reverse rotary . Such snapshots emphasize the dynamic, non-symmetric nature of V1 , differing from more symmetric F1 states.

Proton Translocation in V0

The proton translocation mechanism in the V0 domain of V-ATPase is driven by the rotation of the c-ring rotor, which is mechanically coupled to the V1 domain's activity. Each c-subunit contains a critical residue (aspartate or glutamate) that becomes protonated upon accessing the cytoplasmic half-channel in the a-subunit. This protonated is carried through the hydrophobic core as the c-ring rotates, until it reaches the luminal half-channel, where occurs, releasing the proton into the lumen. The residue in the a-subunit facilitates access and release by forming electrostatic interactions that guide the protonated carboxylates, ensuring unidirectional transport across the . The a-subunit features two half-channels: a cytoplasmic for proton uptake ( site) and a luminal outlet for proton release ( site), separated by a central barrier. These half-channels are gated primarily by electrostatic forces from conserved residues in the a-subunit, which prevent passive proton leakage by stabilizing the deprotonated state of carboxylates in the c-ring during transit. Recent cryo-EM structures have revealed hydrated pathways within these half-channels, where molecules form networks that enable efficient proton via Grotthuss mechanisms, enhancing translocation kinetics. Additionally, , including in contexts, interact with the c-ring periphery, potentially modulating channel accessibility and rotor stability. The of proton translocation is determined by the number of c-subunits in the ring divided by the three catalytic sites in V1, yielding an H⁺/ATP ratio. In mammalian V-ATPases, the c-ring typically consists of 10 subunits (primarily c, with isoforms c′ and c″), resulting in approximately 3.33 protons translocated per ATP hydrolyzed (10/3). This non-integer ratio allows fine-tuned acidification of intracellular compartments. Tight between and proton transport is maintained by interactions involving the a-subunit and accessory elements like subunit d, preventing slippage; however, certain isoforms exhibit partial uncoupling, enabling regulated proton without full in physiological contexts.

Regulation

Reversible Dissociation

The reversible dissociation of V-ATPase represents a key regulatory mechanism that allows the enzyme to rapidly adjust its activity in response to availability, particularly glucose or . In , glucose deprivation triggers the disassembly of the V1 peripheral domain from the V0 , resulting in an autoinhibited V1 complex released into the and a membrane-bound V0 sector that prevents proton leakage while halting . This process occurs within approximately 5-10 minutes of withdrawal, effectively reducing V-ATPase activity by about half and conserving cellular ATP during conditions. Reassembly of V1 and V0 is promptly initiated upon nutrient replenishment, such as glucose addition, through signaling pathways involving (PKA) in and (PI3K) in mammalian cells. The regulator of the H+-ATPase of vacuoles and endosomes () complex plays a central role in this process by binding to the dissociated V1 sector (lacking subunit C) and facilitating its recruitment to V0, often in coordination with other assembly factors. Full reassembly typically completes within about 30 minutes, restoring proton pumping capacity and enabling rapid adaptation to nutrient-rich environments. Physiologically, this mechanism supports energy conservation during nutrient scarcity, as seen in yeast vacuolar acidification, where dissociation prevents unnecessary ATP expenditure on proton translocation. In renal intercalated cells, reversible dissociation enables quick responses to metabolic cues like glucose levels or acid-base shifts, modulating proton secretion into urine to maintain systemic pH balance without sustained high activity. Structurally, dissociation involves the breakage of key interactions at the V1-V0 interface, particularly between the peripheral subunit C in V1 and the rotor-linked subunit d in V0, which disrupts the coupling of to proton translocation. Upon separation, conformational changes in both domains induce autoinhibition: V1 adopts a state where its catalytic sites are non-productive, and V0's proton channel is occluded. This interface-specific decoupling ensures efficient regulation without permanent damage to the .

Accessory Proteins and Modifications

V-ATPase activity is modulated by various accessory proteins that influence its assembly and function without being core structural components. TLDc domain-containing proteins, such as oxidation resistance 1 (Oxr1), act as negative regulators by promoting V-ATPase disassembly. In , Oxr1p binds to the V1 domain and induces dissociation of the V0 and V1 sectors, thereby inhibiting proton pumping, a mechanism conserved in humans where OXR1 and coactivator 7 (NCOA7) similarly suppress activity to prevent excessive acidification in organelles like the Golgi and trans-Golgi network. Conversely, the accessory subunit Ac45 (also known as ATP6AP1) supports V-ATPase assembly and maturation. Ac45 interacts with the V0 integral domain during biosynthesis in the , facilitating subunit folding, glycosylation, and trafficking to lysosomal and plasma membranes, with its absence leading to impaired pump stability and localization.30681-X) Post-translational modifications provide fine-tuned control over V-ATPase enzymatic activity and localization. Phosphorylation by protein kinase A (PKA) at serine residues on the B-subunit inhibits ATP hydrolysis and proton translocation, particularly under low-glucose conditions where it promotes pump disassembly to conserve energy. Protein kinase C (PKC) phosphorylation, meanwhile, enhances V-ATPase trafficking; in renal intercalated cells, PKC activation targets isoforms containing the a-subunit, stimulating apical membrane insertion and acidification in response to stimuli like angiotensin II. Ubiquitination marks V-ATPase subunits for proteasomal degradation, regulating pump levels during lysosomal stress; for example, the late endosomal protein RILP promotes K63-linked ubiquitination of the V1G1 subunit, reducing cytosolic V1 availability and thereby dampening acidification. N-linked glycosylation stabilizes key subunits, such as a4, by preventing misfolding and aggregation, ensuring efficient assembly and plasma membrane targeting, with defects leading to reduced pump activity in distal renal tubules.30681-X) V-ATPase also forms functional complexes with cellular interactors to sense and respond to metabolic cues. The glycolytic aldolase binds directly to V-ATPase subunits (B, C, and E), with interaction strength increasing in high-glucose environments to promote assembly and activity, effectively coupling glycolytic flux to proton pumping for metabolic . In nutrient sensing, V-ATPase associates with the Ragulator complex on lysosomal surfaces, where it acts as an sensor: proton pumping by V-ATPase stimulates Ragulator activity toward Rag GTPases, recruiting and activating to drive anabolic processes under nutrient-replete conditions.00279-4/fulltext) Recent studies have uncovered additional layers of lysosomal V-ATPase involving . The phosphoinositide PIKfyve generates PI(3,5)P2, which is essential for V-ATPase recruitment to lysosomal and phagosomal membranes, maintaining acidification and delivery; inhibition disrupts these processes, leading to vacuolation and impaired degradation. A 2025 study showed that PIKfyve inhibition selectively induces death in senescent cells by suppressing lysosomal , highlighting its therapeutic potential in age-related pathologies.

Evolution

Ancestral Origins with F- and A-ATPases

The V-, F-, and A-ATPases share a common evolutionary origin from a primordial rotary enzyme present in the (LUCA) approximately 4 billion years ago. This ancestral enzyme likely arose from an early event in the RecA family, producing catalytic and non-catalytic subunits that formed the basis of the rotary mechanism. Phylogenetic analyses of genes across bacterial, archaeal, and eukaryotic lineages support this pre-LUCA origin, with the divergence into F-type and A/V-type lineages occurring around or before LUCA. A key aspect of their involves functional reversals and directional divergence. The primordial functioned primarily as a , hydrolyzing ATP to translocate H⁺ ions, as seen in modern V- and A-ATPases, which maintain electrochemical gradients across . In contrast, F-ATPases evolved to synthesize ATP driven by proton gradients, representing a reversal in primary function likely facilitated by gene duplications in catalytic subunits and changes in the c-ring of the domain, adjusting the H⁺/ATP ratio from approximately 2 in pumps to 4 in synthases. These adaptations reflect environmental pressures in early cellular , with F-ATPases becoming prevalent in and inherited by eukaryotic organelles like mitochondria and chloroplasts via endosymbiosis. Among the descendants, archaeal A-ATPases are the closest relatives to eukaryotic V-ATPases, sharing a Vo-like domain (V₀ in V-ATPases) and exhibiting higher sequence identity in their catalytic subunits. The A- and B-subunits of A-ATPases show about 50% identity with those of V-ATPases, compared to only 25% with the α- and β-subunits of F-ATPases, indicating a closer phylogenetic branching for the A/V lineage after the early split from F-types. This similarity underscores the archaeal heritage of V-ATPases, with the archaeal last common ancestor (LACA) estimated at 3.95–3.37 billion years ago. Phylogenetic evidence is bolstered by the conservation of catalytic subunits across all domains of life, with motifs like the Walker-A (GXXXXGKT) preserved in catalytic copies, rooting the rotary family deep in the . Maximum-likelihood trees from over 1,500 sequences confirm four major clades for these subunits, supporting their presence in LUCA. The emergence of V-s in eukaryotes correlates with the development of endomembranes around 2 billion years ago, likely through internalization of an archaeal-like plasma membrane , coinciding with fossil evidence of early eukaryotic complexity such as large organic-walled microfossils. This adaptation enabled acidification of intracellular compartments, a hallmark of eukaryotic cellular .

Subunit Diversification and Isoforms

The diversification of V-ATPase subunits primarily arose through events that enabled the adaptation of this to the increasing complexity of eukaryotic cellular compartments, particularly in multicellular organisms. Core subunits such as , C, D, E, F, G, and the proteolipid c are highly conserved across all eukaryotes, reflecting their ancient origins from a shared prokaryotic , while accessory and regulatory subunits exhibit greater variability. In contrast, multiple isoforms of key subunits emerged in multicellular lineages, allowing tissue- and organelle-specific functions. For instance, the a-subunit of the V0 domain has undergone successive duplications, resulting in four isoforms (a1–a4) in mammals. Similarly, the B-subunits of the V1 domain diversified via vertebrate-specific duplications, producing B1 and B2 isoforms from an ancestral form, with B1 showing tissue-restricted expression patterns. These isoform evolutions reflect selective pressures for specialized roles within the , with phylogenetic analyses indicating that duplications often coincided with the development of complex trafficking pathways in metazoans. The B1/B2 split, for example, occurred through two rounds of whole-genome duplication in early vertebrates, enabling B1 to undergo tissue-specific selection, such as enrichment in and cells, while B2 remains more ubiquitous. For the a-subunit, isoform diversification allowed partitioning across organelles: a1 predominates in lysosomes and endosomes, a2 in the Golgi apparatus and early endosomes, a3 in osteoclasts and secretory lysosomes, and a4 exhibits strong tissue-specificity, particularly in intercalated cells for plasma targeting. This functional divergence is underscored by sequence variations in the N-terminal domains of a-isoforms, which mediate organelle-specific interactions and , with certain mutations in these regions conferring susceptibility to disruptions in proton . Phylogenetic distribution reveals that while single-copy core subunits are universal in eukaryotes, isoform multiplicity is largely confined to multicellular organisms, correlating with the elaboration of the endomembrane network. Recent phylogenomic analyses, including those across insect orders, demonstrate that gene duplications and retroposition events generated paralogous isoforms with tissue-specific expression, such as testis-enriched variants in Drosophila, and highlight conserved regulatory motifs like dCLEAR that coordinate V-ATPase assembly with lysosomal and epithelial functions. These 2023 studies further illustrate co-evolution between V-ATPase isoforms and the endomembrane system, where duplicated subunits adapted to support diverse vesicular trafficking needs in complex tissues.

Associated Diseases

Renal and Skeletal Disorders

(dRTA) arises from dysfunction of V-ATPase in the alpha-intercalated cells of the kidney's collecting duct, impairing proton secretion into the urine and leading to systemic and . This condition is primarily caused by autosomal recessive mutations in genes encoding key V-ATPase subunits, specifically ATP6V1B1 (which codes for the B1 subunit) or ATP6V0A4 (encoding the a4 subunit). Mutations in ATP6V1B1 disrupt the cytoplasmic domain of the V1 sector, reducing ATPase activity and proton pumping efficiency, while ATP6V0A4 alterations affect the membrane-embedded a-subunit, hindering proton translocation across the apical membrane. Clinically, patients present with hyperchloremic , , , and often , particularly with ATP6V1B1 mutations due to co-expression of these isoforms in the . The estimated prevalence of primary dRTA is approximately 1 in 20,000 individuals, with higher rates in regions of . Treatment involves alkali therapy, such as supplementation, to correct and prevent complications like growth retardation and renal damage. Osteopetrosis, particularly the autosomal recessive malignant infantile form, results from V-ATPase defects that impair by , leading to excessively dense yet fragile . in TCIRG1, encoding the a3 subunit of V-ATPase, account for the majority of cases and disrupt acidification of the resorption lacunae, preventing matrix degradation and mineral dissolution. These genetic changes follow an autosomal recessive inheritance pattern and cause ruffled-border formation failure in , resulting in accumulation of calcified and within the marrow space. Clinical manifestations include , , , pathological fractures, and cranial nerve compression, often presenting in infancy with severe morbidity if untreated. For severe cases, serves as the primary curative therapy by replacing defective progenitors, improving and survival rates.

Lysosomal and Neurodegenerative Diseases

Mutations in genes encoding V-ATPase subunits or assembly factors can lead to lysosomal storage disorders characterized by impaired organelle acidification and accumulation of undegraded substrates. For instance, loss-of-function variants in ATP6V0A2, which encodes the a2 isoform of the V0 subunit, cause autosomal recessive type IIA, a condition involving defective due to disrupted Golgi and lysosomal regulation, resulting in abnormalities and substrate buildup in lysosomes. Similarly, mutations in ATP6V0A1, encoding the brain-enriched a1 isoform, dysregulate lysosomal acidification, as observed in models of infantile (INCL), where misrouting of the a1 subunit elevates lysosomal and hinders degradation of accumulated materials like ceroid lipopigment. These defects highlight V-ATPase's critical role in maintaining the acidic environment necessary for lysosomal activity and substrate clearance. X-linked myopathy with excessive autophagy (XMEA) exemplifies V-ATPase dysfunction in muscle, arising from in VMA21, an X-linked essential for V0 domain assembly. These impair V-ATPase proton pumping, leading to autophagic vacuole accumulation without proper degradation, manifesting as progressive proximal , elevated , and vacuolar on . XMEA has an estimated of less than 1 in 1,000,000 individuals, predominantly affecting males with childhood onset, though rare adult-onset cases exist. The condition underscores how failed V-ATPase assembly disrupts -lysosome fusion and flux, causing excessive buildup. The of V-ATPase-related lysosomal and neurodegenerative s centers on defective lysosomal maturation and impaired flux. V-ATPase inhibition or elevates lysosomal , inactivating acid hydrolases and blocking the degradation of autophagocytosed cargos, which leads to accumulation of undigested proteins and . This disrupts endolysosomal trafficking and autophagosome-lysosome fusion, as V-ATPase activity is required for recruiting fusion machinery like SNAREs and RAB proteins. In neuronal contexts, such impairments exacerbate protein aggregate buildup, contributing to cellular and progression. V-ATPase dysfunction is implicated in neurodegenerative diseases through impaired clearance of pathogenic proteins. In , reduced V-ATPase activity hinders lysosomal acidification, compromising amyloid-β degradation and autophagy-mediated clearance, as evidenced by lysosomal pH dysregulation in affected neurons. Similarly, in , V-ATPase impairment disrupts α-synuclein degradation via the autophagy-lysosome pathway, with studies showing that modulation of V-ATPase subunits like ATP6V0C can restore autophagic flux and reduce α-synuclein levels. A 2024 review synthesizes genetic evidence linking V-ATPase variants to these disorders, emphasizing their role in acidification and . Recent findings reveal that TLDc domain-containing proteins modulate neuronal V-ATPase function, influencing disease susceptibility. TLDc proteins, including OXR1 and NCOA7, interact with V-ATPase to regulate its assembly and activity, preventing excessive acidification in compartments like the Golgi and trans-Golgi network while supporting lysosomal . Mutations in TLDc genes impair this regulation, leading to altered proton pumping and heightened vulnerability in neurons, with implications for and neurodegeneration. These interactions position TLDc proteins as potential therapeutic targets for restoring V-ATPase balance in lysosomal disorders.

Oncogenic and Other Pathologies

V-ATPase plays a critical role in cancer progression through its upregulation and relocation to the plasma membrane of tumor cells, where it drives extracellular acidification of the . This acidification activates matrix metalloproteinases (MMPs) and other proteases, facilitating tumor invasion and . For instance, the a2 isoform (ATP6V0A2) is overexpressed in invasive and ovarian cancers, promoting neutrophil migration and enhancing metastatic potential via autocrine IL-8 secretion. Overexpression of V-ATPase subunits is observed in numerous cancers, including , pancreatic, and gastric, correlating with poor and increased invasiveness. Specific mutations in V-ATPase genes are rare in cancers, with dysregulation primarily driven by overexpression and altered isoform distribution rather than genetic alterations. The proton extrusion by plasma membrane-localized V-ATPase maintains an alkaline , which supports the Warburg effect by enabling sustained and lactate production even under aerobic conditions. This metabolic shift provides rapid energy and biosynthetic intermediates essential for tumor proliferation. In cancer cells, V-ATPase-mediated H+ export counters the acidification from glycolytic lactate, preventing intracellular and promoting cell survival and growth. Therapeutic targeting of V-ATPase has shown promise in , with inhibitors such as A1 and concanamycin A inducing , inhibiting , and sensitizing tumor cells to . For example, V-ATPase inhibition reverses cisplatin resistance in cells by disrupting homeostasis and enhancing drug uptake. These inhibitors also overcome resistance to inhibitors in non-small cell by blocking endosomal acidification and receptor recycling. Beyond oncology, V-ATPase contributes to other pathologies through its acidification functions. In pancreatic β-cells, the a3 isoform (ATP6V0A3) regulates insulin granule acidification, which is essential for proper proinsulin processing and glucose-stimulated insulin secretion; disruptions impair β-cell function and may contribute to . V-ATPase also facilitates viral entry by acidifying endosomes, enabling uncoating of viruses such as and . Emerging 2024-2025 research highlights V-ATPase's involvement in via its interaction with , where dysregulation promotes lysosomal dysfunction, , and obesity-related metabolic imbalances.

Nomenclature and Isoforms

Subunit Nomenclature

The nomenclature for subunits of the vacuolar-type H⁺-ATPase (V-ATPase) adheres to standards set by the (HGNC), which designates human genes with the prefix ATP6V followed by a numeral indicating the structural domain—1 for the peripheral V₁ sector or 0 for the membrane-embedded V₀ sector—then the subunit identifier and, where applicable, a numerical suffix for isoforms. For instance, ATP6V1A encodes the A subunit of the V₁ domain, while ATP6V0A1 encodes the a1 isoform of the V₀ domain's a subunit. Subunit identifiers distinguish the domains through lettering conventions: V₁ subunits are labeled with uppercase letters A through H, reflecting their catalytic and regulatory roles, whereas V₀ subunits use lowercase letters a through e to denote transmembrane components. This system originated from studies in the yeast , where genes were historically named VMA (vacuolar membrane ATPase) followed by numbers, such as VMA1 for the A subunit homolog. Efforts to unify began in the , incorporating insights from homologies with bacterial F-ATPases and archaeal A-ATPases to standardize across eukaryotes and resolve prior inconsistencies like disparate symbols (e.g., ATP6A1 or ATP6N1). The current framework was formalized in 2003 by the Human and Mouse Committees, extending to isoform suffixes for paralogs arising from duplications; examples include ATP6V1B1 and ATP6V1B2 for the two B subunit isoforms in V₁. HGNC-approved symbols include unique identifiers and chromosomal locations, such as ATP6V1B1 (HGNC:853) at locus 2p13.3.
DomainSubunit ExampleGene SymbolHGNC IDNotes
V₁AATP6V1A851Catalytic subunit; no isoform number needed for single copy.
V₁B1ATP6V1B1853Isoform 1; located at 2p13.3.
V₁B2ATP6V1B2854Isoform 2; distinguishes paralog.
V₀a1ATP6V0A1865Isoform 1 of a subunit.
V₀dATP6V0D113724d1 isoform; one of two d isoforms (with ATP6V0D2).
This tabular representation highlights key examples without exhaustive listing, emphasizing the systematic progression from domain to subunit and isoform.

Isoform Classification and Expression

V-ATPase exhibits isoform diversity primarily through multiple variants of its subunits, enabling tissue-specific and organelle-targeted functions. The a-subunit of the V0 domain has four principal isoforms in humans, encoded by distinct genes: ATP6V0A1 (a1), ATP6V0A2 (a2), ATP6V0A3 (), and ATP6V0A4 (a4). These isoforms direct the pump to specific cellular locations, such as intracellular compartments for a1 and a2, or plasma membranes for a3 and a4. The B-subunit of the V1 domain features two isoforms: ATP6V1B1 (B1) and ATP6V1B2 (B2), with B1 restricted to specialized epithelial cells and B2 present broadly across cell types. Expression of these isoforms is tightly regulated in a tissue-specific manner to support localized acidification needs. For instance, the a4 isoform is highly enriched in the alpha-intercalated cells of the kidney collecting duct, where it facilitates proton extrusion, while a3 predominates in osteoclasts and pancreatic beta cells. The B1 isoform is confined to proton-secreting epithelia, including the kidney distal tubule, inner ear, and olfactory epithelium, contrasting with the ubiquitous distribution of B2 in intracellular vesicles and endomembranes across most tissues. Developmental regulation further refines this pattern; a3 expression surges during osteoclast differentiation, transitioning from low levels in precursor mononuclear cells to high abundance in mature, multinucleated osteoclasts, aligning with increased resorptive activity.02501-2/fulltext) Functional specializations arise from these isoform distributions, allowing tailored proton transport. The a1 isoform supports synaptic vesicle acidification in neurons, essential for loading and release, whereas a2 contributes to endosomal and Golgi pH maintenance in various cell types, including endothelial cells and renal proximal tubules. In contrast, a3 enables plasma membrane proton pumping in osteoclasts for and in secretory granules of endocrine cells, while a4 drives apical H+ secretion in renal and epididymal epithelia. For the B-subunits, B1 enhances proton secretion efficiency at specialized plasma membranes, as seen in renal acid-base , with B2 fulfilling general intracellular roles and capable of partial compensation in B1-deficient contexts.02501-2/fulltext) Genomic organization of V-ATPase genes is dispersed across , with each a-isoform located separately; for example, ATP6V0A1 resides on 17q21.2, and ATP6V0A4 on 7q34. is infrequent but occurs in select cases, generating variants like a1-I through a1-III for neuronal targeting or a4-I and a4-II differing in their N-terminal exons for tissue adaptation. The B-isoform genes, ATP6V1B1 and ATP6V1B2, similarly lack extensive clustering or splicing diversity. Database resources such as provide comprehensive annotations of these isoforms, cataloging over 20 distinct human V-ATPase variants across all 14 core subunits as of 2025 updates, incorporating sequence alignments, expression data, and functional notes derived from proteomic and genomic studies.

References

  1. https://www.nature.com/articles/nrm2272
  2. https://www.cell.com/trends/biochemical-sciences/fulltext/S0968-0004(20)30005-0
  3. https://www.nature.com/articles/s41586-024-07610-x
  4. https://www.pnas.org/doi/10.1073/pnas.1814818116
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7508768/
  6. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00510/full
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9280200/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5112157/
  9. https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-017-0395-1
  10. https://journals.biologists.com/jcs/article/127/23/4987/54688/The-vacuolar-type-H-ATPase-at-a-glance-more-than-a
  11. https://pubmed.ncbi.nlm.nih.gov/12672822/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5995505/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2907102/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11660900/
  15. https://pubmed.ncbi.nlm.nih.gov/29464568/
  16. https://doi.org/10.1016/j.molcel.2020.09.029
  17. https://doi.org/10.1038/s41467-020-17762-9
  18. https://www.science.org/doi/10.1126/science.aaz2924
  19. https://www.nature.com/articles/s41467-020-17762-9
  20. https://www.nature.com/articles/s41467-022-28832-5
  21. https://www.embopress.org/doi/10.15252/embj.201593447
  22. https://www.sciencedirect.com/science/article/pii/S0969212624000911
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC2154418/
  24. https://www.pnas.org/doi/10.1073/pnas.2217181120
  25. https://pubs.acs.org/doi/10.1021/bi100397s
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10352029/
  27. https://www.pnas.org/doi/10.1073/pnas.2210204119
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9963935/
  29. https://www.jbc.org/article/S0021-9258(19)60982-8/fulltext
  30. https://www.nature.com/articles/s41594-025-01610-9
  31. https://www.jbc.org/article/S0021-9258(19)72908-1/fulltext
  32. https://www.sciencedirect.com/science/article/pii/S0021925820745412
  33. https://rupress.org/jcb/article/142/1/39/1031/Assembly-of-the-Yeast-Vacuolar-H-ATPase-Occurs-in
  34. https://www.sciencedirect.com/science/article/pii/S0021925820478767
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC5957294/
  36. https://doi.org/10.1016/j.devcel.2023.10.007
  37. https://doi.org/10.1091/mbc.E18-04-0234
  38. https://doi.org/10.3389/fmolb.2023.1168680
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC10166205/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC9586324/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC11638961/
  42. https://doi.org/10.1016/j.jbc.2023.102884
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC12533636/
  44. https://www.nature.com/articles/s41467-024-53504-x
  45. https://www.science.org/doi/10.1126/science.adp5577
  46. https://elifesciences.org/articles/56862
  47. https://www.science.org/doi/10.1126/sciadv.1600725
  48. https://www.embopress.org/doi/10.1038/s44319-024-00126-5
  49. https://portlandpress.com/biochemj/article/462/1/185/47025/Reversible-disassembly-of-the-yeast-V-ATPase
  50. https://www.pnas.org/doi/10.1073/pnas.2414511121
  51. https://www.jbc.org/article/S0021-9258%2819%2960982-8/fulltext
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC2683016/
  53. https://www.jbc.org/article/S0021-9258%2818%2980959-0/pdf
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3339975/
  55. https://www.jbc.org/article/S0021-9258%2820%2953076-7/pdf
  56. https://www.pnas.org/doi/10.1073/pnas.2505975122
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC3951719/
  58. https://onlinelibrary.wiley.com/doi/10.1155/2014/675430
  59. https://www.nature.com/articles/srep14827
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3798730/
  61. https://journals.biologists.com/jcs/article/127/12/2697/54447/RILP-regulates-vacuolar-ATPase-through-interaction
  62. https://pubmed.ncbi.nlm.nih.gov/27127844/
  63. https://www.sciencedirect.com/science/article/pii/S0021925817477726
  64. https://www.mdpi.com/2073-4409/13/11/953
  65. https://www.biorxiv.org/content/10.1101/2025.03.19.644224v1
  66. https://www.nature.com/articles/s41467-023-42924-w
  67. https://journals.biologists.com/jeb/article/172/1/137/6560/Evolution-and-isoforms-of-V-ATPase-subunits
  68. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2004.08.065
  69. https://www.researchgate.net/publication/20628297_Evolution_of_the_vacuolar_H-ATPase_Implications_for_the_origin_of_eukaryotes
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC10313074/
  71. https://www.nature.com/articles/srep03217
  72. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1168680/full
  73. https://www.mdpi.com/2079-7737/12/8/1127
  74. https://www.nature.com/articles/s41419-020-2354-y
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC4867564/
  76. https://www.kidney-international.org/article/S0085-2538%2817%2930001-7/fulltext
  77. https://www.ncbi.nlm.nih.gov/books/NBK547595/
  78. https://www.revistanefrologia.com/en-distar-renal-tubular-acidosis-drta--articulo-S201325142100002X
  79. https://www.kidney.org/kidney-topics/drta-how-it-treated
  80. https://medlineplus.gov/genetics/gene/tcirg1/
  81. https://academic.oup.com/hmg/article/9/13/2059/627368
  82. https://pubmed.ncbi.nlm.nih.gov/35981697/
  83. https://emedicine.medscape.com/article/123968-clinical
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC6436016/
  85. https://www.genenames.org/data/genegroup/#!/group/415
  86. https://doi.org/10.1016/S1097-2765(03)00397-6
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC2835735/
  88. https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/853
  89. https://pubmed.ncbi.nlm.nih.gov/10722719/
  90. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0045395
  91. https://www.ncbi.nlm.nih.gov/gene/535
  92. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2023.1135015/full
  93. https://pubmed.ncbi.nlm.nih.gov/16621796/
Add your contribution
Related Hubs
User Avatar
No comments yet.